October 30, 2007
Lung Cancer Radiation Scarring is Studied
A U.S. radiological study suggests preventing lung scarring during radiation therapy for lung cancer might extend patients' lives.
Researchers at New York University Medical Center have found that using a special type of drug called a pharmaceutical monoclonal antibody to prevent a serious side effect of radiation therapy for lung cancer patients -- pulmonary fibrosis, or scarring of the lungs -- extends patients' lives and improves their quality of life.
More than 50 percent of patients receiving radiation therapy for advanced lung cancer develop radiation-induced lung fibrosis, the scientists said.
The research findings were presented this week in Los Angeles during the annual meeting of the American Society for Therapeutic Radiology and Oncology.